News
Browse all news articles and resources.
Featured
3 articles
A Chicago Fund Is Bridging Ketamine's Coverage Gap
A Chicago nonprofit is stepping in where insurers won't, covering ketamine treatment costs for patients with depression who can't afford to wait.
A Chicago Fund Is Closing Ketamine's Access Gap
A Chicago nonprofit is stepping in where insurers won't, funding ketamine treatment for depression patients who can't afford out-of-pocket costs.
Esketamine's Role in Treatment-Resistant Depression
Clinicians are turning to esketamine for TRD and suicidal depression. Here's what patients need to know about access, cost, and how it compares to IV ketamine.
A Chicago Fund Is Bridging Ketamine's Coverage Gap
A Chicago nonprofit is stepping in where insurers won't, covering ketamine treatment costs for patients with depression who can't afford to wait.
A Chicago Fund Is Closing Ketamine's Access Gap
A Chicago nonprofit is stepping in where insurers won't, funding ketamine treatment for depression patients who can't afford out-of-pocket costs.
Esketamine's Role in Treatment-Resistant Depression
Clinicians are turning to esketamine for TRD and suicidal depression. Here's what patients need to know about access, cost, and how it compares to IV ketamine.
Why Settling for 'Less Bad' Depression Isn't Enough
Clinicians are pushing for aggressive TRD care aimed at full remission. Here's what that means for patients exploring ketamine treatment options.
BXCL501 Enters Phase 2a Trial for Acute Stress & PTSD
A new DoD-backed Phase 2a trial is testing BXCL501 for acute stress reactions. Here's what it means for the evolving PTSD treatment landscape.
BPL-003 Shows Lasting TRD Relief in Phase 2a Results
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. Here's what it means for ketamine patients.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
New clinical thinking on treatment-resistant depression urges aggressive care aimed at full remission — not just symptom reduction. Here's what it means for patients.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
Ketamine Compounding Regulations in 2026: What Has Changed
An overview of the latest regulatory developments affecting compounded ketamine in 2026, including FDA enforcement updates, state-level changes, and the impact on patient access.
Ketamine Clinic Safety Standards: What Patients Should Expect
An overview of emerging safety standards for ketamine treatment clinics, including clinical protocols, monitoring requirements, provider qualifications, and what patients should look for when evaluating a ketamine provider.
DEA Telehealth Prescribing Rules: What Changed in 2025
An overview of the DEA's evolving telehealth prescribing regulations for controlled substances, including ketamine, and how the 2025 rule changes affect patients and providers under the Ryan Haight Act.
Compounding Pharmacies and Ketamine: What Patients Should Know
What patients should know about compounding pharmacies that prepare ketamine formulations, including quality standards, regulatory oversight, and how to choose a pharmacy.
State-Level Ketamine Therapy Regulations: 2025 Landscape
An overview of the evolving state-level regulatory landscape for ketamine therapy in 2025, including telehealth rules, prescribing restrictions, and supervision requirements.
The Rise of At-Home Ketamine Treatment Companies
An analysis of the growing at-home ketamine therapy industry, including major companies, business models, clinical concerns, and what patients should know before enrolling.
Key Ketamine Research Developments in 2025
A roundup of the most important ketamine research findings, clinical trials, and scientific developments shaping the field in 2025.
FDA Esketamine (Spravato) Updates
A summary of the latest FDA regulatory actions, label updates, and clinical developments related to esketamine (Spravato) for depression treatment.
Ketamine Insurance Coverage: 2025 Trends and Developments
A look at the evolving insurance landscape for ketamine therapy in 2025, including Spravato coverage changes, off-label coverage, and what patients should know.
Telehealth Ketamine: Evolving Regulations
An overview of the changing regulatory landscape for telehealth-based ketamine prescribing, including federal policy, state-level rules, and safety considerations.
International Ketamine Research: Global Developments and Discoveries
A roundup of significant ketamine research from around the world, including clinical trials, regulatory developments, and scientific discoveries outside the United States.